Helminth infection and type 2 diabetes mellitus in Indonesia

Conditions

Soil-transmitted helminth infection Infections and Infestations Helminthiasis, unspecified

Farid Kurniawan, Dicky L. Tahapary, Karin de Ruiter, Em Yunir, Nienke R. Biermasz et al. (10 authors)

Scientific Reports2020-11-045 citations

10.1038/s41598-020-75781-4

The Effect of Helminths on Granulocyte Activation: A Cluster-Randomized Placebo-Controlled Trial in Indonesia

Karin de Ruiter, Dicky L. Tahapary, Erliyani Sartono, Thomas B. Nutman, Johannes W. A. Smit et al. (8 authors)

The Journal of Infectious Diseases2018-11-145 citations

10.1093/infdis/jiy665

2-methyl butyramide, a previously identified urine biomarker for Ascaris lumbricoides, is not present in infected Indonesian individuals.

Lagatie O, Njumbe Ediage E, Pikkemaat JA, Djuardi Y, Stuyver LJ.

2017-12-294 citations

10.1186/s13071-017-2600-z

Helminth infections and type 2 diabetes: a cluster-randomized placebo controlled SUGARSPIN trial in Nangapanda, Flores, Indonesia.

Tahapary DL, de Ruiter K, Martin I, van Lieshout L, Guigas B, Soewondo P, Djuardi Y, Wiria AE, Mayboroda OA, Houwing-Duistermaat JJ, Tasman H, Sartono E, Yazdanbakhsh M, Smit JW, Supali T.

2015-03-1837 citations

10.1186/s12879-015-0873-4

Interventions

Households are randomized to two groups: 1. 400 mg albendazole 2. Placebo Given orally for 3 consecutive days, every 3 months. Patients are followed up

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Those who have given informed consent 2. Both males and females 3. Aged 16 years or older 4. Live in Nangapanda area, Flores Island 5. Good health, without any serious clinical condition

Exclusion criteria

Exclusion criteria: 1. Subjects younger than 16 years 2. Active treatment for diabetes mellitus 3. Serious concomitant disease 4. Pregnant women 5. No informed consent

Design outcomes

Primary

Measure	Time frame
Changes in insulin resistance as assessed by HOMA-IR (Homeostatic Model of Assessment-Insulin Resistance), one year post treatment	—

Secondary

Measure	Time frame
Energy metabolism and immunological parameters related to energy metabolism, measured one year post treatment. 1. Changes in body mass index and waist circumference measured by SECA tools 2. Changes in serum fasting blood glucose and HBA1c using a glucose meter 3. Changes in serum lipid levels, measured by commercial enzymatic kits 4. Changes in helminth load, measured by polymerase chain reaction (PCR) 5. Changes in immune polarization: FACS, intracellular staining, enzyme-linked immunosorbent assay (ELISA)	—

Measure

Time frame

Energy metabolism and immunological parameters related to energy metabolism, measured one year post treatment. 1. Changes in body mass index and waist circumference measured by SECA tools 2. Changes in serum fasting blood glucose and HBA1c using a glucose meter 3. Changes in serum lipid levels, measured by commercial enzymatic kits 4. Changes in helminth load, measured by polymerase chain reaction (PCR) 5. Changes in immune polarization: FACS, intracellular staining, enzyme-linked immunosorbent assay (ELISA)

—

Countries

Indonesia

Outcome results

None listed